Collagen biosynthesis and modifying enzymes R-HSA-1650814

Collagen is the most abundant protein in the human body and provides the structural scaffold of skin, bone, tendon, cartilage, blood vessels and basement membranes. The Reactome pathway Collagen biosynthesis and modifying enzymes (R-HSA-1650814) captures the complete intracellular and extracellular route by which collagen propeptides are synthesized, enzymatically modified, folded into triple helices and assembled into fibrils. Because collagen defines the mechanical and signaling properties of nearly every tissue, the pathway is a recurring entry point for research on development, fibrosis, cancer stroma and inherited connective-tissue disease. The pathway is unusually enzyme-rich. Proline and lysine residues within the triple-helical domain are hydroxylated by prolyl 3-, prolyl 4- and lysyl hydroxylases, and hydroxylysine residues serve as sites for glycosylation and for covalent cross-linking between collagen molecules in fibrils. These modifications are not decorative: 4-hydroxyproline is essential for intramolecular hydrogen bonding and stability of the triple helix, and the extent of hydroxylation varies between tissues and collagen types. Collagen propeptides also carry non-collagenous N- and C-terminal domains that direct chain association and, once cleaved, can act as biologically active fragments. For researchers, R-HSA-1650814 is a practical map for experimental design. It links 40 collagen genes to a defined set of modifying enzymes and processing steps, so a knockout, point mutation, knock-in or overexpression model can be positioned precisely within the biosynthetic pipeline. The pathway also connects to microenvironmental inputs such as hypoxia and ascorbic acid availability, which influence collagen biosynthesis and matrix quality. What Is the Collagen biosynthesis and modifying enzymes Pathway? Collagen biosynthesis and modifying enzymes (R-HSA-1650814) is the Reactome pathway that describes how human collagen alpha chains are produced and matured. Collagen propeptides are cotranslationally translocated into the endoplasmic reticulum, where proline and lysine residues are hydroxylated by prolyl 3-, prolyl 4- and lysyl hydroxylases, and hydroxylysine residues can be glycosylated. Intra-chain disulfide bonds form in the N-propeptide, and the C-propeptide folds and is stabilized by disulfide bonds; pro-alpha chains then associate through their C-propeptides or NC2 domains to form an initial trimer. The triple helix nucleates and folds in a C-to-N direction, and procollagen is released into the extracellular space. Fibrillar procollagens undergo removal of C- and N-propeptides by Zn2+-dependent metalloproteinases, yielding tropocollagen, which aggregates into fibrils that are stabilized by lysyl oxidase-catalyzed cross-links. The pathway therefore spans synthesis, enzymatic modification, folding, propeptide processing and fibril assembly.

Collagen biosynthesis and modifying enzymes (R-HSA-1650814) is the Reactome pathway that describes how human collagen alpha chains are produced and matured. Collagen propeptides are cotranslationally translocated into the endoplasmic reticulum, where proline and lysine residues are hydroxylated by prolyl 3-, prolyl 4- and lysyl hydroxylases, and hydroxylysine residues can be glycosylated. Intra-chain disulfide bonds form in the N-propeptide, and the C-propeptide folds and is stabilized by disulfide bonds; pro-alpha chains then associate through their C-propeptides or NC2 domains to form an initial trimer. The triple helix nucleates and folds in a C-to-N direction, and procollagen is released into the extracellular space. Fibrillar procollagens undergo removal of C- and N-propeptides by Zn2+-dependent metalloproteinases, yielding tropocollagen, which aggregates into fibrils that are stabilized by lysyl oxidase-catalyzed cross-links. The pathway therefore spans synthesis, enzymatic modification, folding, propeptide processing and fibril assembly.

R-HSA-1650814 matters because collagen is the principal structural protein of the extracellular matrix and because the pathway's modifying enzymes determine whether collagen is mechanically stable, correctly cross-linked and appropriately assembled. Defects at any step, from hydroxylation to propeptide cleavage to fibril cross-linking, produce connective-tissue pathology, and the same enzymes are increasingly implicated in cancer progression and matrix remodeling. Understanding the pathway therefore supports both mechanistic cell biology and translational work in inherited disease, fibrosis and oncology.

The pathway includes 40 human collagen genes spanning fibrillar, network-forming, FACIT, transmembrane and other collagen subfamilies, each contributing distinct chains to specific matrices.

Collagen biosynthesis is regulated at multiple levels. The extent of proline 4-hydroxylation, 3-hydroxyproline formation and lysine hydroxylation varies between tissues and collagen types, so enzyme activity and substrate context set the modification pattern. Prolyl 4-hydroxylase activity has been linked to alpha-chain association, since no association of the C-propeptides of type XII collagen was seen in the presence of prolyl 4-hydroxylase inhibitors. Propeptide processing is a required step for normal collagen I and III fibril formation, and retained type V and XI N-propeptides sterically limit lateral molecule addition, providing a built-in brake on fibril growth. Microenvironmental factors such as hypoxia and ascorbic acid are interconnected regulators of collagen biosynthesis. Collagen-modifying enzymes are also distributed in a tissue-specific manner, as shown by their localization on fibroblastic reticular cells and follicular dendritic cells in lymphoid tissues.

Mutations in collagen genes and in the enzymes that modify them cause a spectrum of connective-tissue disorders. Collagens and their modifying enzymes are recurrent mutation sites in human disease, and the vascular aspects of Ehlers-Danlos syndromes illustrate how defective collagen compromises vessel wall integrity. Because the pathway spans hydroxylation, folding and cross-linking, pathogenic variants can act at several distinct steps rather than at a single node.

Collagen IV is the principal structural collagen of basement membranes, and its biosynthesis requires precise intracellular post-translational modification. Loss of the collagen IV modifier prolyl 3-hydroxylase 2 causes thin basement membrane nephropathy, directly linking a single modifying enzyme in R-HSA-1650814 to kidney disease. This makes collagen IV modification a tractable entry point for nephrology research.

Collagen-modifying enzymes contribute to tumor progression through matrix remodeling. Lysyl hydroxylase 2 glucosylates collagen VI to drive lung cancer progression, demonstrating that a pathway enzyme can directly promote malignancy. Hypoxia, a common feature of solid tumors, is interconnected with ascorbic acid availability in driving collagen biosynthesis, so the pathway sits at the interface of tumor metabolism and matrix biology.

Collagen-modifying enzymes are localized on fibroblastic reticular cells and follicular dendritic cells in non-neoplastic and neoplastic lymphoid tissues, indicating that the pathway contributes to lymphoid organ architecture. This extends the relevance of R-HSA-1650814 beyond classical connective tissue into immunology and lymphoid neoplasia.

RNA-seq of collagen genes and modifying enzymes provides a first-pass map of pathway activity across tissues and disease states, and can be paired with proteomics to detect hydroxylated and glycosylated collagen peptides. Because the extent of hydroxylation varies between tissues and collagen types, transcript abundance alone is insufficient and should be interpreted alongside modification data.

Hydroxylation and glycosylation status can be assessed by targeted mass spectrometry and by enzyme-activity assays for prolyl 3-, prolyl 4- and lysyl hydroxylases. Collagen IV biosynthesis studies illustrate how such assays resolve the intracellular choreography of post-translational modifications.

Fluorescent tagging of collagen chains and modifying enzymes allows tracking of ER folding, secretory trafficking and extracellular fibril formation. Fibril morphology and cross-linking can be evaluated by electron microscopy and by lysyl oxidase-dependent cross-link measurements.

Pathway-responsive reporters combined with controlled hypoxia and ascorbic acid conditions can test how microenvironmental inputs alter collagen biosynthesis. Such assays are useful for separating transcriptional from post-translational control of the pathway.

R-HSA-1650814 is a large, enzyme-rich pathway in which the functional consequence of a perturbation depends on which chain or modification step is affected. EDITGENE provides the cell-model and screening toolkit needed to interrogate this pathway at the level of individual genes, specific variants and whole-pathway readouts, supporting both mechanistic studies and translational programs in connective-tissue disease, cancer and matrix biology.

R-HSA-1650814 provides a complete, stepwise map of collagen biosynthesis and modifying enzymes, from ER translocation and hydroxylation through triple-helix folding, propeptide processing and fibril cross-linking. Its 40 collagen genes and associated enzyme families make it a rich source of experimental targets for inherited connective-tissue disease, kidney basement-membrane disorders and cancer matrix biology. Because the pathway's output depends on precise post-translational modification, CRISPR models that isolate individual genes or variants are especially informative for mechanistic and translational research.